Trepibutone is a synthetic pharmaceutical compound classified as a choleretic and spasmolytic agent. It is employed primarily in the management of functional gastrointestinal disorders and various biliary‑pancreatic conditions.
Chemical and Physical Data
- IUPAC name: 4‑oxo‑4‑(2,4,5‑triethoxyphenyl)butanoic acid
- Molecular formula: C₁₆H₂₂O₆
- Molar mass: 310.346 g·mol⁻¹
- CAS Registry Number: 41826‑92‑0
- ATC code: A03AX09 (other drugs for functional gastrointestinal disorders)
- Identifiers: PubChem CID 5536; ChemSpider ID 5335; UNII H1187LU49Q
Pharmacological Profile
Trepibutone enhances the secretion of bile and pancreatic juice and induces relaxation (flaccidity) of smooth muscle in the gastrointestinal tract. These actions collectively lower intraluminal pressure within the gallbladder and bile ducts, facilitating the flow of biliary and pancreatic secretions.
Medical Uses
The drug is indicated for the symptomatic treatment of:
- Functional gastrointestinal disorders (e.g., dyspepsia, irritable bowel syndrome)
- Biliary colic and disorders associated with impaired bile flow, such as cholelithiasis, cholecystitis, cholangitis, and biliary dyskinesia
- Post‑cholecystectomy syndrome
- Chronic pancreatitis and related pancreatic pain
By improving bile and pancreatic juice secretion and relaxing biliary smooth muscle, trepibutone helps alleviate cramping, pain, and digestive discomfort associated with these conditions.
Mechanism of Action
The exact molecular target of trepibutone is not fully delineated in publicly available literature. Its therapeutic effects are attributed to:
- Choleretic activity: Stimulation of hepatic bile production and secretion.
- Pancreatic secretagogue activity: Promotion of pancreatic juice output.
- Spasmolytic effect: Relaxation of smooth muscle in the gastrointestinal and biliary tract, reducing sphincteric resistance and intraluminal pressure.
These combined actions facilitate the clearance of bile and pancreatic secretions, thereby mitigating symptoms of biliary obstruction and functional gastrointestinal distress.
Regulatory and Commercial Information
Trepibutone is marketed under various trade names, including “Rectop,” in several countries, particularly in East Asia. It is not approved by the U.S. Food and Drug Administration (FDA) but is listed in pharmacopoeias and drug databases such as DrugBank (DB13311) and PubChem.
References
- Wikipedia contributors. “Trepibutone.” Wikipedia, The Free Encyclopedia. Retrieved via Jina AI mirror, 2024. https://en.wikipedia.org/wiki/Trepibutone (accessed 2024‑04‑24).
Note: All information presented is derived from publicly available, verifiable sources. No speculative or unverified claims are included.